The largest insider buys this week were for Fastenal Co. (FAST, Financial), Phillips 66 Partners LP (PSXP, Financial), Cantel Medical Corp. (CMD, Financial) and Harpoon Therapeutics Inc. (HARP, Financial).
Fastenal director bought 18,000 shares
Director Darren R. Jackson bought 18,000 shares on Jan. 23 for an average price of $35.57. The share price has decreased by 0.14% since then.
Fastenal is an American industrial supply company that focuses on distributing industrial, safety and construction supplies. It has over 2,600 branches throughout the United States, Mexico and Canada. The company has a market capitalization of $20.39 billion; as of Jan. 24, it traded at $35.52.
On Jan. 17, Fastenal reported financial results for the fourth quarter of 2019. Net sales for the quarter were $1.27 billion, compared with net sales of $1.23 billion in the prior-year quarter. Gross profit $598.4 million, compared to $587.8 million a year ago.
Phillips 66 Partners director bought 1,640 shares
Director Mark Haney bought 1,640 shares on Jan. 22 for an average price of $62.17. The stock has declined 3.67% since then.
Phillips 66 Partners is a master limited partnership formed by Phillips 66. The company focuses on acquiring, operating and developing fee-based crude oil, refined petroleum products and natural gas liquids pipelines and other midstream assets. The company has a market capitalization of $13.63 billion; as of Jan. 24, it traded at $59.89.
On Jan. 21, Phillips 66 Partners announced the board of directors had declared a fourth-quarter cash dividend of 87.5 cents per common share, representing an increase of 1 cent from the third quarter. The dividend is payable on Feb. 13 to shareholders of record at the close of business on Jan. 31.
Cantel Medical director bought 2,000 shares
Director Mark N. Diker bought 2,000 shares on Jan. 17 for an average price of $62.43. The price has increased by 8.11% since then.
Cantel Medical is an American company that specializes in the production of medical equipment. The company has four subsidiaries, including Medivators, Crosstex, Mar Cor Purification and Saf-T-Pak. The company has a market capitalization of $2.87 billion; as of Jan. 24, it traded at $67.49.
On Dec. 18, Cantel Medical announced its board of directors had approved an increase of 0.05 cents in its semi-annual cash dividend, from 10 cents to 10.5 cents per share. The dividend will be payable on Jan. 31 to shareholders of record at the close of business on Jan. 17.
Harpoon Therapeutics chief financial officer bought 6,700 shares
CFO Georgia Erbez bought 6,700 shares on Jan. 21 for an average price of $14.09. The stock has gained 3.76% since then.
Harpoon Therapeutics is an American clinical-stage immunotherapy company that focuses on developing novel classes of T cell engagers to treat patients suffering from cancer and other diseases. The company has its own proprietary Tri-specific T cell Activating Construct platform to develop a pipeline of novel T cell constructs for the treatment of solid tumors. The company has a market capitalization of $360.22 million; as of Jan. 24, it traded at $14.62.
On Nov. 6, Harpoon Therapeutics reported financial results for the third quarter of 2019. The net loss for the quarter was $15.9 million, compared to a net loss of $6.8 million a year ago. The company ended the quarter with $121.2 million in cash and cash equivalents, compared to $89.5 million at the end of the prior-year period. Revenue for the quarter was $1.4 million, compared to $1.1 million.
For the complete list of stocks that were bought by their company executives, go to Insider Trades.
Disclosure: I do not own stock in any of the companies mentioned in the article.
Not a Premium Member of GuruFocus? Sign up for a free 7-day trial here.
